A Review of Autologous Stem Cell Transplantation in Lymphoma

Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, Ahmad Iftikhar, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations


Purpose of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary: Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

Original languageEnglish (US)
Pages (from-to)217-226
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Issue number3
StatePublished - Jun 1 2017


  • Autologous stem cell transplantation
  • High-dose chemotherapy
  • Lymphoma
  • Novel agents
  • Relapsed/refractory
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A Review of Autologous Stem Cell Transplantation in Lymphoma'. Together they form a unique fingerprint.

Cite this